# Beijing StarMab BioMed Technology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/beijing-starmab-biomed-technology

- Industry: Pharmaceuticals
- Headquarters: Beijing, China
- Website: www.starmab.com.cn
- Total disclosed funding: $16M
- Latest round: Series A (Feb 28, 2024)
- Investors on record: 5

## About

Founded in 2019 and based in Beijing, China, Beijing StarMab BioMed Technology Ltd is a biotech company that focuses on the development of antibody drugs. Dr. Yanbin Liang, the founder of the company, has worked for Eli Lilly and Allergan in the United States. The company has research and development bases in Beijing and California. In 2022, the firm completed in vitro and animal efficacy POC, monkey PK and toxicity studies. In 2023, the company's SM3321 injection received clinical approval from the NMPA. In February 2024, it closed a series A+ funding.

The company's main products include SM3321, SM1542 and SM009. The unique binding site of SM3321 drug can strongly target tumor cells, activate immune cell function, and reduce non-specific toxic reactions. The company's products are used in oncology, inflammation and neurodegenerative diseases.

## Funding rounds

- Series A, Feb 28, 2024 — Zhuhai Science & Technology Venture, Guangda Huitong Engineering Technology Research Institute Capital
- Series A, Feb 21, 2022, $16M — China International Capital Corporation, Chang'an Capital, Huajin Lingchuang Fund Management

## Investors

- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series A
- Chang'an Capital (https://capitalatlas.ai/funds/chang-an-capital) — Series A
- Huajin Lingchuang Fund Management (https://capitalatlas.ai/funds/huajin-lingchuang-fund-management) — Series A
- Zhuhai Science & Technology Venture — Series A
- Guangda Huitong Engineering Technology Research Institute Capital (https://capitalatlas.ai/funds/guangda-huitong-engineering-technology-research-institute-ca) — Series A